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criteria, of which 3,152 (15.1%) underwent additional diagnostic imaging in the 6 
months post-index. White women were 1.12 times more likely to be recalled than 
African-American women (p< 0.001). Average costs per patient recalled were $838 
among white women and $804 among African-American women. Overall, 28.6% 
of costs were from additional imaging (diagnostic mammography and/or ultra-
sound), 39.2% were from guided biopsy procedures, and 24.4% from open biopsy. 
Recall-related office visits, MRI, fine needle aspiration, and ductogram accounted 
for < 5% of recall costs. Individual recall procedure rates were substantively simi-
lar between White and African-American recalled patients but African-American 
women had higher per-patient imaging costs and lower per-patient open biopsy 
costs. CONCLUSIONS: Improving breast cancer screening with a more accurate 
mammogram may significantly reduce Medicaid costs as approximately one-in-six 
women undergo additional diagnostic imaging following a screening mammogram 
with substantial associated costs. Recall rate and costs varied by race.
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OBJECTIVES: To describe the burden of recall following traditional screening mam-
mography from the perspective of US self-insured employers. METHODS: The 
Truven Health MarketScan Commercial and Health and Productivity Management 
Databases were used to identify female employees aged 40-65 years undergo-
ing screening mammography (index event) in 2010-2012 with at least 12 months 
pre- and 6 months post-index continuous enrollment; patients with a breast 
cancer diagnosis in the pre-index period were excluded. Recall was defined as 
receipt of diagnostic mammogram or ultrasound in the six months following the 
index screen. Employer cost per recall (2013 US$) was the sum of breast-related 
imagining procedures and associated diagnostic procedure costs in the 6 months 
post-index, excluding patient payments and breast cancer treatment costs. 
Absenteeism costs were calculated using a wage constant ($38/hour). RESULTS: 
Of the 339,912 patients who met the study criteria, 47,321 (13.4%) underwent 
additional diagnostic imaging within 6 months post-index with an average direct 
medical cost to employers of $1,279 per patient recalled. Nearly one-fourth (23.4%) 
of recall costs was attributable to additional imaging (diagnostic mammography 
or ultrasound), 40.0% was attributable to guided biopsy and 28.0% attributable to 
open biopsy. One-fifth (21.9%) of recalled patients had at least two days with recall-
related procedures while 4.2% had at least three recall event days. Absenteeism 
costs were $948 in the 30 days following recall among patients with absenteeism 
claims (67.2%), increasing to $4,472 over 6 months post-recall among patients with 
absenteeism claims (81.9%). Short-term disability claims increased following recall 
(4.0% vs. 4.4%, p< 0.01), with an average cost per claim of $10,849. CONCLUSIONS: 
Recall following traditional mammography represents a significant cost burden to 
employers with nearly one-in-six female employees with a new screening mam-
mogram undergoing additional diagnostic imaging and associated procedures. 
Strategies to reduce the burden of recall should not ignore indirect employer 
costs.
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OBJECTIVES: Current cost studies describing people with epilepsy do not segment 
the populations by seizure type. This paper produces an economic model of people 
experiencing seizures, including individuals with epilepsy, broken into novel cat-
egories useful in assessing the potential effect of future interventions. METHODS: 
Three-year’s worth of administrative claims data from Milliman’s commercially-
insured research dataset (n= 16.8 million 2012) was grouped into benefit service 
cost categories. Individuals experiencing seizures were extracted whose coverage 
included prescription drugs and whose medical claims contained the following 
ICD9CM diagnosis codes: 345.00, 345.01, 345.10, 345.11, 345.2, 345.3, 345.40, 345.41, 
345.50, 345.51 and 780.33. Individuals were grouped into three novel categories: 
Motor Seizures (345.10, 345.11, 345.3, 345.40, and 345.41), Post Traumatic Seizures 
(780.33) and Non-Motor Seizures (345.00, 345.01, 345.2, 345.50, and 345.51). RESULTS: 
Individuals experiencing seizures represented 0.4% of the population and accounted 
for 1.8% of allowed claims dollars. The odds of being admitted to the hospital for 
the Motor and Non-Motor Seizure groups were 5.5 and 4 times higher, respectively, 
with a 2-day longer average length of stay and total allowed claims dollars were 
5 and 4.2 times higher, respectively, than the standard population. The odds of 
being admitted for the Post Traumatic group was 9 times higher with an average 
length of stay almost 4 days longer and total allowed claims dollars were 6 times 
higher than the standard population. Other cost and utilization measures produced 
similar results. CONCLUSIONS: Individuals experiencing seizures are expensive 
when compared to the standard population. The excess utilization is in manageable 
healthcare cost categories. By utilizing these novel groups, case managers may find 
new ways to manage patients with epilepsy, target interventions and measure the 
success of those interventions.
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OBJECTIVES: In 2011, PhilHealth, the Philippine national health insurance provider, 
switched to a case rate scheme in tandem with a policy which prevents govern-
67 clinical records were analyzed. The average cost per CHKV children patient was 
US$517.5 (US$756.9 in equal or older than 1 year old, and US$375.1 in under one 
year population). The average length of stay was 2,7 days per patient. More prescript 
drugs were oral rehydration salts and acetaminophen. The more requested labs were 
hematic chart (13.8%) and protein C reactive (7.57%). CONCLUSIONS: Despite CHKV 
infection is not a lethal disease, it would cause a very huge impact in the health 
services and it associated cost in Colombia. Cost per case in children is high, and 
probably would be similar or higher in adult population.
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OBJECTIVES: To determine the direct cost of health care technologies used for treat-
ment of hypothyroidism in Ukraine. METHODS: We made the retrospective analysis 
of 81 patients’s medical records with hypothyroidism that were hospitalized to 
the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The 
method of pharmacoeconomic analysis “cost of illness” was used to estimate the 
cost of health care for patients with hypothyroidism. We have made calculations 
of costs: the cost of laboratory analysis, the cost of instrumental analysis, the cost 
of drug treatment, doctor’s consultations, costs of patient’s stay in hospital. While 
determining the direct costs of medical services in monetary terms we used the 
rates for medical services that were in Ternopil University Hospital. RESULTS: The 
study found that among the patients there were 23 (28.4%) men and 58 (71.6%) 
women aged 19 to 77 years (46.86±10.03). All patients have got to the hospital in 
stage of medication subcompensation. The average duration of stay in hospital for 
patients was 10.77±1.95 days. The total cost of laboratory tests was USD 4,231.95. The 
costs of instrumental methods of patients examination amounted USD 576.90. The 
cost of consultations by specialists was USD 769.36. In determining the amount of 
direct costs for medicines we found that the cost of drug treatment of the underlying 
disease was USD 52.40, the cost of drug therapy of hypothyroidism complications 
was USD 3,932.21. Total cost of patients stay in hospital was USD 9,411.80. After cal-
culation of all direct costs we determined that the total cost of hypothyroidism per 
patient is USD 234.26 per course of treatment. CONCLUSIONS: In the cost structure 
of health care provision for patients with hypothyroidism the most significant costs 
were spent for laboratory tests and for patient’s stay in hospital. The presence of 
underlying disease complications significantly increases cost of drugs.
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OBJECTIVES: To evaluate the clinical and economic impact of the incorporation of 
the monovalent conjugate vaccine against meningitis C caused by the Neisseria 
meningitides bacterium in children aged 0-4 years in the Brazilian public health 
system. METHODS: The analysis was developed for the period of 2009 to 2013. Were 
considered the actual number of cases of the disease recorded in the Notification 
Information System and deaths from meningitis C obtained from the Mortality 
Information System, and the estimates of long-term sequelae (amputation, skin 
scarring, renal failure, neurological sequelae and deafness) and of the costs due 
to sequelae, disease and vaccination. RESULTS: From 2009 to 2013, a decrease in 
the quantity of cases (684, 651, 563, 399 and 300, respectively) and in the number of 
deaths due to meningococcal meningitis (134, 111, 68, 61 and 47, respectively) was 
observed. There was also a reduction in the costs related with disease manage-
ment (R$ 1,572,632.28, R$ 1,496,759.67, R$ 1,294,432.71 and, R$ 917,368.83, respec-
tively) and with meningococcal meningitis sequelae (R$ 342,551.14, R$ 336,322.94, 
R$ 308,296.02, R$ 210,513.24 and, R$ 157,573.52, respectively). The three doses of 
the vaccine for children in their first year of life cost to the public treasury (R$ 
0.00, R$ 270,863,108.24, R$ 266,933,428.24, R$ 263,150,498.68 and, R$ 259,515,275.33, 
respectively). Therefore, the estimate of the value spent by the government in 
the evaluated years was R$ 1,915,183.42, R$ 272,696,190.85, R$ 268,536,156.97, R$ 
264,278,380.76 and, R$ 260,362,599.85. CONCLUSIONS: The Vaccine against menin-
gococcal meningitis type C implementation in SUS (Unique Health System - Sistema 
Único de Saúde in Portuguese) – the national public health system in Brazil – in 
infants in their first year of life generated reduction of incidence, mortality and 
sequelae due to the disease, decreasing, over the years, the cost due to the disease 
and to its sequelae, although adding the cost with vaccination.
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OBJECTIVES: To describe the prevalence of patient recall in the six months following 
traditional screening mammography and the related costs to Medicaid by patient 
race. METHODS: The Truven Health MarketScan Medicaid Multi-State Database was 
used to identify women aged 40-75 years undergoing screening mammography 
(index event) in 2010-2012. Women were required to have 12 months pre- and 6 
months post-index continuous enrollment and were excluded if they had mam-
mography or a breast cancer diagnosis in the 12 month pre-index period. Recall 
was defined as receipt of diagnostic mammogram or ultrasound in the six months 
following the index screen; patients with a subsequent breast cancer diagnosis were 
excluded from recall counts or costs. Payer cost per recall (2013 US$) was the sum 
of breast-related imagining and diagnostic procedures in the 6 months post-index, 
excluding patient payments and breast cancer treatment costs. RESULTS: A total of 
20,838 women undergoing a new screening mammogram met the study selection 
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OBJECTIVES: To study the cost related to the management of type 2 diabetes mel-
litus (T2DM) in public health care by standard approach as a means to assist in the 
evaluation of health services in Brazil. METHODS: A small municipality was con-
sidered for this study, with less than 50,000 habitants, it is representative of 81% of 
the state’s municipalities and 89% of Brazil’s. The data sources used were obtained 
from the Municipal Health Office and public data systems online. Direct medical 
costs were selected according to standard care recommended by the Ministry of 
Health and Brazilian Associations of Cardiology and Diabetes, and lately divided 
into three categories of analysis: Health professional salary, Procedures and tests 
costs, and Medication costs, both for Primary Health Care (PHC) and Medium/High 
Complexity Care (MHCC). RESULTS: In 2011, the total expense in a year for a user 
with T2DM was U$ 491.04, regarding the individual without complication, attended 
in PHC. After developing chronic complications (either microvascular or macro-
vascular), the patient continues to receive PHC, but also needs the attention of 
specialists, therefore costs for specific treatments in MHCC services were added to 
the PHC costs. The sum ranged from U$ 732.86 for nephropathy to U$ 3182.59 for 
Acute Myocardial Infarction. In evaluation of each category of analysis, the invest-
ment made by the National Health System in the management of T2DM showed 
uneven distribution, where a subcategory of Health professionals salary, the PHC’s 
doctors salary, represented an important share of spending in exchange of others 
categories. CONCLUSIONS: The standard cost method is presented as an alterna-
tive that offers greater convenience and flexibility in the determination of costs 
to assist health managers in decision-making, considering the shortcomings of 
Brazilian’s information system.
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OBJECTIVES: To measure the cost associated with an acute coronary event through 
a retrospective cohort study of patients in Saludcoop EPS, Cafesalud Cruz Blanca 
EPS and EPS during the first six months of 2013 in Colombia. METHODS: Through 
a retrospective analysis of 2943 patients with acute coronary event were identified 
with ICD-10-associated acute coronary syndrome, which were reported by each 
of the EPS to the Ministry of Health and Social Protection of Colombia. The first 
part of the study involved the characterization of the population by age group, 
gender, region and comorbidities. The second part includes an analysis of the 
use of hospital services and average stay in the hospital. In the third part the 
analysis included the average cost of interventions such as angioplasty, heart 
surgery and thrombolysis during the first six months after the acute coronary 
event were included. RESULTS: The male population has a higher incidence of 
acute coronary event at a younger age than that of the female population. The 
male population of the department of Antioquia recorded the most interventions 
received. The average cost per patient with acute coronary event during the first 
month was 14,381,501 Colombian Pesos and 2,493,801 Colombian Pesos per patient 
during the sixth month. CONCLUSIONS: the first month represented the highest 
cost for acute coronary event with an average of 13,382,501 COP, which is 53.35% 
of the total cost per event.
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OBJECTIVES: To assess the impact of clinical pharmacist intervention (CPI) on pre-
scribing habit and cost saving throughout 12 months duration for patients receiving 
some and the same medications include (Human Albumin 20% 50ml, Meropenem 
500 mg and Ciprofloxacin 200 mg), this was via a comparison made between the 
NO-CPI (observation only) and Direct-CPI phases, in term of the number of vials 
dispensed monthly. METHODS: It is an observational cohort study and it is divided 
into two phases; Phase-I: to evaluate prescribing habit of the prescribers throughout 
two months duration (30 days with NO-CPI and 30 days with Direct-CPI) for patient 
using Human Albumin. While phase-II: to assess the impact of Direct-CPI versus 
NO-CPI on cost saving throughout 10 months duration ( 5 months with NO-CPI and 5 
months with Direct-CPI). The number of dispensed vials for each item was recorded 
by CP. RESULTS: The study findings in phase-I showed that Direct-CPI lead to statis-
tically significant (P < 0.0001) improvement of prescribing for human albumin 20%, 
especially in cases with albumin level > 3 g/dl, it was 36% with NO-CPI versus 1.6% 
with Direct-CPI, and in cases with albumin level < 2 g/dl, and it was 6% with NO-CPI 
versus 42% with Direct-CPI. In phase II, during 5-months of Direct-CPI compared 
with the same duration of No-CPI, there was a remarkable monthly cost saving, and 
it was 54% for Human Albumin, 55% for Meropenem and 59% for Ciprofloxacin. This 
resulted in total cost saving for all three items equal to 123,735 US Dollar during 
the five months of Direct-CPI. CONCLUSIONS: Direct-CPI can significantly improve 
prescribing habit and lead to a substantial cost saving.
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WITHDRAWN
ment hospitals from charging patients in situations where that total admission 
cost exceeds the case rate. These policies aim to provide financial protection to 
patients while promoting efficiency in hospitals. There are concerns that tertiary 
government hospitals might end losing money as they managed mostly compli-
cated cases. To assess this possibility, the cost of admission for pneumonia cases 
admitted in the internal medicine ward of a tertiary government hospital in the 
Philippines was estimated. The proportion of pneumonia admissions where costs 
did not exceed case rates was also determined. METHODS: A random sample of 
admissions for pneumonia for two severity classes (moderate-risk and high-risk) 
from January 1 to June 30 2013 was obtained. Costs considered were diagnostic 
tests, medications, mechanical ventilator use and overhead costs. Due to the lack 
of billing reports, costs of diagnostics tests and medications were computed via 
tallies from chart review. Overhead costs were estimated using WHO-CHOICE 2007 
values for the Philippines. RESULTS: A sample of 112 moderate-risk and 42 high-risk 
pneumonia cases were included in the study. The mean total costs were US$ 564.55 
for moderate-risk and US$ 727.01 for high-risk. 29.5% of moderate-risk cases had a 
total cost less than the case rate of US$ 333 and 68.2% of high-risk cases had a total 
cost less than the case rate of US$ 711.11. Considering costs and reimbursements 
for all admissions, the hospital will lose US$ 25,895.11 due to moderate-risk and 
US$ 2,121.77 due to high-risk admissions. CONCLUSIONS: Estimated mean total 
costs exceed the case rates of PhilHealth for pneumonia. The case rates may not 
be adequate to cover the total costs of admission in a government tertiary hospital 
in the Philippines.
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OBJECTIVES: Compare direct costs of medical care before and after heart failure (HF) 
hospitalization in a Medicare population. METHODS: A 5% (n= 3,493,434) national 
sample of Medicare beneficiaries for the years 2006-2012 was used to identify indi-
viduals with at least 65 years of age at the date of hospital admission for HF, enrolled 
in Medicare Parts A and B and not enrolled in a Medicare Advantage plan. Total costs 
were summed (in constant 2012 dollars) for all services utilized by the hospitalized 
beneficiary every month during observation the period. The total costs for each 
month before, after and during the month of HF hospitalization were plotted. Costs 
of an HF episode were calculated as difference in total reimbursements in the six 
months during and after the month of hospitalization and the six months preced-
ing the event. The incremental analysis allows individuals to serve as their own 
controls. RESULTS: There were 63,678 eligible episodes of HF hospitalizations. In the 
six months prior to the month of hospitalization total costs were $14,212 and in the 
six months following discharge, total costs were $24,645. The cost (total costs for all 
services utilized) during the month of hospitalization was $14,967. CONCLUSIONS: 
The cost of care in the six months following a HF hospital discharge was more 
than $10,000 higher than those in 6 months prior to the hospitalization. Avoiding 
hospitalizations for patients with HF would be desirable not only because they are 
costly but also because the cost of care remains higher for at least six months fol-
lowing the hospitalization.
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OBJECTIVES: To measure the intervention costs of the Pharmacists’ Pneumonia 
Prevention Project (PPPP), a community-based pneumonia education and vaccina-
tion program administered to older Philadelphians in 2014. METHODS: PPPP involved 
a pharmacist informational presentation, a live skit, small-group breakouts, and 
optional vaccination. Attendees could consent to participate in program assess-
ments if they were aged 50+, cognitively intact, and English speaking. Recruitment 
and program coordination were completed through partnerships with churches and 
senior centers. The total cost from a health system perspective was the sum of time 
costs (pharmacy, community health workers; CHWs for travel, training, supervision 
and planning), supplies (vaccine, medical, and office supplies), actor and site fees. 
Time requirements for each program date were recorded using a staff log. Wages 
were applied to time using U.S. Bureau of Labor Statistics rates plus fringe ben-
efits applicable to each partnering institution. Volunteer pharmacy students were 
assigned zero time costs. RESULTS: Among 276 individuals who attended PPPP, 203 
consented to program assessments and were mostly female (74.9%), black (80.4%), 
and the mean age was 74. PPPP was offered on 8 dates at 4 community locations. 
Mean staff requirements for each date were 5.5 students, 3.6 pharmacists, and 2 CHW. 
The total program cost was $32,513 (per-attendee cost = $118). Time costs associated 
with planning ($11,927), program delivery ($8,659), and non-volunteer travel ($2,257) 
represented 70.3% of the total cost. Time and expenses for vaccination ($7,861) also 
contributed substantially to PPPP costs (24.2%), while actors’ fees ($1,750) represented 
5.4%. Excluding vaccination costs and actor costs would yield per-attendee costs of 
$89.32 and $82.98, respectively. CONCLUSIONS: Resources requirements for PPPP are 
high, but will be further evaluated in terms of outcomes achieved (knowledge gains, 
vaccination rate). Costs could be offset by reimbursement for vaccination, omitting 
this component, and/or using a video skit rather than live actors.
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